Ryan Deschner
Stock Analyst at Jefferies
(4.77)
# 86
Out of 4,853 analysts
12
Total ratings
81.82%
Success rate
47.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Downgrades: Hold | $15 → $4 | $3.99 | +0.25% | 2 | May 16, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Outperform | $75 → $52 | $19.10 | +172.25% | 1 | May 9, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $18.02 | +60.93% | 3 | May 9, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $6.74 | +330.27% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $3.64 | +257.14% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $13.44 | +108.33% | 3 | Jan 14, 2025 | |
Inozyme Pharma
May 16, 2025
Downgrades: Hold
Price Target: $15 → $4
Current: $3.99
Upside: +0.25%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Outperform
Price Target: $75 → $52
Current: $19.10
Upside: +172.25%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $18.02
Upside: +60.93%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $6.74
Upside: +330.27%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $3.64
Upside: +257.14%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $13.44
Upside: +108.33%